NMR LipoProfile vs Lipid Panel: What the Particle Test Adds, Who Actually Needs It, and When ApoB Is the Smarter Upgrade

Cholesterol does not float free in blood; it rides inside lipoprotein particles, and it is the particles — specifically the ones that carry apolipoprotein B, chiefly LDL — that enter the artery wall and start plaque. A standard lipid panel reports the cholesterol cargo: how many milligrams of cholesterol the LDL particles are carrying per deciliter (LDL-C), the same for HDL, and triglycerides. The NMR LipoProfile uses nuclear magnetic resonance to count the vehicles: the number of LDL particles per liter (LDL-P), how many are small, the average particle size, the HDL particle count, and — from the particle pattern — a score for insulin resistance. For most people cargo and vehicle count rise and fall together, so the $19.99 panel tells the story. In roughly one person in four or five, they diverge: many small, cholesterol-poor LDL particles produce a reassuring LDL-C and a high LDL-P — the pattern of high triglycerides, low HDL, diabetes and metabolic syndrome — and in that group the particle number, not the cholesterol, predicts the heart attack. That is the whole case for particle testing, and it is also why ApoB — one molecule per atherogenic particle, measurable for $29.99 — answers the central question for most people without the NMR price.

Four numbers from one tube: total cholesterol; HDL cholesterol (the cholesterol inside HDL particles); triglycerides; and LDL cholesterol, at most labs calculated from the other three rather than measured directly — which is why a very high triglyceride (above 400 mg/dL) makes the LDL-C unreliable and why a fast is requested so triglycerides are at baseline. From these the lab or your clinician derives non-HDL cholesterol (total minus HDL), which approximates the cholesterol in all the atherogenic particles together and is the better of the two for people with high triglycerides. The 2018 ACC/AHA guideline builds the ten-year risk calculator, the statin thresholds and the treatment targets on these values. A lipid panel is cheap, standardized across every lab in the country, and sufficient for most screening — the lipid panel cost guide covers how to get one for the least money, and the LDL, HDL and triglycerides pages explain each value.

The NMR LipoProfile (a Labcorp-developed test; TestWell draws it at Quest or Labcorp) exposes the plasma to a magnetic field and reads the signal each lipoprotein particle class gives off, so it counts and sizes particles directly rather than measuring the cholesterol inside them. The report adds to the standard lipids:

• LDL particle number (LDL-P), in nmol/L — the headline value. Report cutpoints: below 1,000 optimal; 1,000–1,299 near or above optimal; 1,300–1,599 borderline high; 1,600–2,000 high; above 2,000 very high.
• Small LDL-P — the count of small, dense LDL particles, the ones most associated with insulin resistance; below about 527 nmol/L is the optimal band.
• LDL size — average particle diameter in nanometers; above 20.5 nm is "Pattern A" (large, buoyant), at or below it "Pattern B" (small, dense).
• HDL particle number (HDL-P) — a count rather than a cholesterol amount; higher is better, and it tracks protection somewhat better than HDL-C.
• Large VLDL-P — the triglyceride-rich particles that rise with excess carbohydrate, alcohol and insulin resistance.
• LP-IR score (25–100) — an insulin-resistance index computed from the particle pattern: 45 or below is insulin-sensitive, above 63 insulin-resistant, in between intermediate. It flags metabolic trouble before glucose or A1c move, which is the feature no other lipid test offers.

The draw is identical to a lipid panel — one tube, after a 9–12 hour fast so the triglyceride-rich particles are at baseline — and results take 3–5 business days rather than 1–3.

The evidence for counting particles comes from discordance. In the Framingham Offspring Study, people whose LDL-P was high while their LDL-C was low had cardiovascular event rates that followed the particle number; in MESA, when the two markers disagreed by a meaningful margin, carotid plaque and events tracked LDL-P and not LDL-C. Discordance is not rare, and it clusters: triglycerides above about 150 mg/dL, HDL-C below 40 (men) or 50 (women), type 2 diabetes or prediabetes, abdominal obesity and the metabolic syndrome all push the liver to make many small, cholesterol-poor LDL particles — a normal-looking LDL-C hiding a high particle count. The reverse pattern (high LDL-C, lower-than-expected LDL-P, large buoyant particles) is seen in some lean, insulin-sensitive people and in some on a very-low-carbohydrate diet, and carries less risk than the cholesterol number suggests.

So particle testing is worth the money when: your triglycerides are high or HDL low; you have diabetes, prediabetes or a fasting insulin that is creeping up; your LDL-C is "fine" but a parent or sibling had a heart attack or stent before 60; you have had a cardiac event or coronary calcium with unremarkable lipids; or you are on a statin and want to know whether what is left is real residual risk. It is not needed for a first screen in a healthy adult, for tracking a statin dose when LDL-C and ApoB already agree, or in place of a lipid panel — the NMR includes the standard lipids, but the guidelines' thresholds are written for the panel values.

Every atherogenic particle — LDL, VLDL, IDL, Lp(a) — carries exactly one molecule of apolipoprotein B, so a plasma ApoB concentration is a particle count by another method. Across large cohorts and trials, ApoB predicts events at least as well as LDL-C and non-HDL-C and reconciles most of the discordance that LDL-C misses. Unlike LDL-P it appears in the major guidelines: the 2018 ACC/AHA guideline lists an ApoB of 130 mg/dL or higher as a risk-enhancing factor that favors starting a statin in borderline cases, and the 2019 ESC/EAS guideline recommends ApoB for risk assessment — and prefers it over LDL-C — in people with high triglycerides, diabetes, obesity, metabolic syndrome or a very low LDL-C. It is a routine immunoassay, so it costs $29.99 rather than $63.99, is standardized across labs, and needs no fasting on its own. What ApoB does not give you is particle size, the small-LDL count, HDL-P or the LP-IR score — so choose NMR when the insulin-resistance read-out matters to you, and ApoB when the question is simply "how many bad particles do I have." The ApoB test page and the ApoB biomarker page cover targets; the advanced heart health blood tests guide places ApoB, Lp(a), hs-CRP and NMR side by side.

• LDL-C and LDL-P both low (LDL-C under 100 mg/dL, LDL-P under 1,000 nmol/L): concordant and low-risk; follow the lipid panel from here.
• LDL-C low or borderline, LDL-P high (LDL-P above 1,300 with an LDL-C under 130): the discordance that matters. Expect high triglycerides, a high small LDL-P and an LP-IR above 45. Treat the particle number and the insulin resistance — weight, carbohydrate load, activity, and a clinician's conversation about statin or other therapy based on your overall risk.
• LDL-C high, LDL-P proportionally high: concordant and high; the lipid panel alone would have made the same call.
• LDL-C high, LDL-P lower than expected (large Pattern A particles, low triglycerides, LP-IR under 45): lower risk than the cholesterol number implies, but not none — a lifetime of high LDL-C still matters, and a clinician weighs it with family history, Lp(a) and calcium scoring.
• LP-IR above 63 with normal glucose: insulin resistance before the sugar shows it. Fasting insulin and A1c are the follow-up tests.

Whatever the particle pattern, two things neither test tells you: Lp(a), the inherited particle that raises risk independently and is measured once in a lifetime (Lp(a) test, $32.99), and inflammation (hs-CRP). The Heart Health Panel bundles the lipid panel with ApoB, Lp(a) and hs-CRP for $99.99.

Through TestWell, drawn at Quest or Labcorp with one $6 lab fee per order: Lipid Panel $19.99 (results in 1–3 business days); ApoB $29.99 (2–4 business days); NMR LipoProfile $63.99 (3–5 business days, includes the standard lipids, so you do not need to buy both). Fast 9–12 hours before the lipid panel or the NMR — water, black coffee and medications are fine. A licensed physician authorizes the order, the requisition is emailed, most locations take walk-ins, and results post to your account with the lab's cutpoints and a plain-language summary; the NMR report's particle values come with the LipoScience bands above.

A concordant, low result on either test is a number to recheck every four to six years in a healthy adult, sooner with new risk factors. A high LDL-C, a high LDL-P or an ApoB at or above 130 mg/dL is a conversation with a clinician about your ten-year and lifetime risk — the ACC/AHA calculator uses the lipid-panel values, and particle numbers or ApoB tilt borderline decisions. A high LP-IR or small LDL-P with normal cholesterol is a metabolic signal: it responds to weight loss, fewer refined carbohydrates and more activity within months, and it is worth rechecking with fasting insulin and A1c. Chest pain, pain or pressure with exertion, or shortness of breath are not lipid-test questions — they are a same-day evaluation.